Skin bioequivalents and their role in the treatment of inherited epidermolysis bullosa

Archives of Dermatology

Volumn 136, Issue 10, 2000, Pages 1259-1260

  Fine, J D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ARTICLE; DEVICE; EDITORIAL; EPIDERMOLYSIS BULLOSA; GENE THERAPY; HUMAN; KERATINOCYTE; PRIORITY JOURNAL; SKIN GRAFT; WOUND DRESSING; WOUND HEALING;

EID: 0033778127     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.136.10.1259     Document Type: Editorial

References (8)

1. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds
2. The use of tissue engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa
3. Treatment of junctional epidermolysis bullosa with epidermal autografts
4. Successful engraftment of allogeneic keratinocyte cultures in recessive dystrophic epidermolysis bullosa
5. Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa
6. Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production
7. Peripheral blood mononuclear cell subsets in patients with severe inherited forms of epidermolysis bullosa
8. The DEBRA International Visioning/Consensus Meeting on Epidermolysis Bullosa: Summary and recommendations